8-K: Mineralys FDA Accepts Lorundrostat NDA, Reports FY25 Results

Mineralys Therapeutics announced FDA acceptance of its New Drug Application for lorundrostat for hypertension, setting a PDUFA target date of December 22, 2026, alongside its Q4 and full-year 2025 financial results.

Summary

• The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for lorundrostat for the treatment of hypertension, assigning a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.
• The company completed five positive clinical trials for lorundrostat in hypertension, demonstrating clinically meaningful blood pressure (BP) reduction, 24-hour control, and a favorable safety profile.
• The Explore-OSA Phase 2 trial for lorundrostat in obstructive sleep apnea (OSA) did not demonstrate a clinically meaningful difference relative to placebo on AHI (apnea-hypopnea index), the primary endpoint.
• In the Explore-OSA trial, lorundrostat demonstrated a clinically meaningful reduction in blood pressure at week four, with an 11.1 mmHg (p < 0.0001) reduction compared to 1.0 mmHg (p = NS) with placebo in the pre-planned parallel arm analysis, and a 6.2 mmHg placebo-adjusted reduction (p < 0.0003) in the crossover analysis.
• Cash, cash equivalents, and investments were $656.6 million as of December 31, 2025, a significant increase from $198.2 million as of December 31, 2024.
• Research and Development (R&D) expenses for the year ended December 31, 2025, decreased to $132.0 million from $168.6 million in 2024, primarily due to the conclusion of the lorundrostat pivotal program.
• General and Administrative (G&A) expenses for the year ended December 31, 2025, increased to $38.6 million from $23.8 million in 2024, mainly due to headcount growth and professional fees.
• Net loss for the year ended December 31, 2025, was $154.7 million, an improvement from a net loss of $177.8 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, primarily driven by the FDA's acceptance of the NDA for lorundrostat in hypertension, a significant step towards commercialization. The strong cash position further supports future operations, despite the setback in the Explore-OSA trial's primary endpoint.

Positives

• FDA accepted the New Drug Application (NDA) for lorundrostat for hypertension, a significant regulatory milestone.
• A PDUFA target date of December 22, 2026, has been assigned, providing a clear timeline for potential regulatory approval.
• The company successfully completed five positive clinical trials for lorundrostat in hypertension, demonstrating clinically meaningful blood pressure reduction and a favorable safety profile.
• Cash, cash equivalents, and investments significantly increased to $656.6 million as of December 31, 2025, from $198.2 million in 2024, providing sufficient funding into 2028.
• Net loss for the full year 2025 decreased to $154.7 million from $177.8 million in 2024.
• Lorundrostat demonstrated a clinically meaningful reduction in blood pressure in the Explore-OSA trial, despite missing the primary endpoint for AHI.

Negatives

• The Explore-OSA Phase 2 trial did not demonstrate a clinically meaningful difference relative to placebo on AHI (apnea-hypopnea index), the primary endpoint, for obstructive sleep apnea.
• General and Administrative (G&A) expenses increased to $38.6 million for the year ended December 31, 2025, from $23.8 million in 2024, primarily due to headcount growth and higher professional fees.

Risks

• Topline results reported are based on preliminary analysis and may change following a more comprehensive review, potentially not accurately reflecting complete clinical trial results.
• Any delays in the FDA's review of the accepted NDA, including as a result of government shutdowns or reductions in agency funding or personnel, could impact approval timelines.
• The results of clinical trials, including Advance-HTN and Launch-HTN, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat.
• Later developments with the FDA may be inconsistent with feedback from prior meetings, potentially affecting the registration of lorundrostat.
• Future company performance is entirely dependent on the success of lorundrostat.
• Potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies.
• Dependence on third parties in connection with manufacturing, research, and clinical and nonclinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat may limit its development, regulatory approval, and/or commercialization.
• Unfavorable results from clinical trials and nonclinical studies.
• Results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results.
• Macroeconomic trends and uncertainty, including high interest rates, elevated inflation, tariffs, and the potential for economic recession.
• Ability to maintain undisrupted business operations due to any pandemic or future public health concerns.
• Regulatory developments in the United States and foreign countries.
• Reliance on an exclusive license with Tanabe Pharma Corporation to provide intellectual property rights to develop and commercialize lorundrostat.

Future Outlook

The company believes its current cash, cash equivalents, and investments of $656.6 million will be sufficient to fund planned clinical trials, regulatory activities, and corporate operations into 2028. They anticipate working closely with the FDA towards potential approval and commercialization of lorundrostat for hypertension, with a PDUFA target date of December 22, 2026. Analysis for other endpoints in the Explore-OSA trial is ongoing and will be reported in future publications or medical meetings.

Management Comments

• "Mineralys had a transformational year in 2025, defined by significant clinical progress and key regulatory milestones." Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.
• "We successfully completed multiple clinical trials, with results published in JAMA and The New England Journal of Medicine, highlighting the potential of lorundrostat to benefit patients with inadequately controlled hypertension." Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.
• "The FDAs acceptance of this application marked a significant milestone, and we look forward to working closely with the agency as lorundrostat advances toward potential approval and commercialization." Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.

Industry Context

StockSavvy.ai notes that the FDA's acceptance of the NDA for lorundrostat positions Mineralys Therapeutics as a significant contender in the hypertension market, an area with substantial unmet need given that less than 50% of patients achieve their blood pressure goals with existing medications. The focus on dysregulated aldosterone, which drives hypertension in approximately 30% of patients, targets a specific mechanism that could offer a differentiated treatment option. While the miss on the primary endpoint in the Explore-OSA trial for AHI is a setback for that specific indication, the continued demonstration of blood pressure reduction in that trial reinforces lorundrostat's core efficacy in hypertension, which remains the primary and most advanced indication.

Comparison to Industry Standards

• The 11.1 mmHg blood pressure reduction observed in the Explore-OSA trial (and previously in pivotal trials) for lorundrostat is clinically meaningful and compares favorably to other novel antihypertensive agents or add-on therapies, which often aim for reductions in the 5-10 mmHg range.
• Lorundrostat's 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro is a strong indicator of its targeted mechanism, potentially leading to a more favorable side effect profile compared to less selective mineralocorticoid receptor antagonists.
• The PDUFA target date of December 22, 2026, is a standard timeline for novel drug approvals following NDA acceptance, aligning with typical regulatory review periods for new molecular entities.

Stakeholder Impact

• Shareholders: Positive impact due to significant regulatory progress (NDA acceptance) for the lead drug candidate and a strong cash position, potentially increasing future valuation upon approval.
• Patients (Hypertension): Potential for a new, effective treatment option for uncontrolled or resistant hypertension, especially those with dysregulated aldosterone.
• Patients (Obstructive Sleep Apnea): No immediate benefit for OSA patients from lorundrostat based on the primary endpoint miss in the Explore-OSA trial, though blood pressure benefits were observed.
• Employees: Increased headcount and compensation expenses suggest growth and stability within the company, particularly in preparation for potential commercialization.

Next Steps

• FDA review process for lorundrostat NDA, with a PDUFA target date of December 22, 2026.
• Ongoing analysis for other endpoints in the Explore-OSA trial, with results to be reported in future publications or medical meetings.
• Continued gathering of additional long-term safety and efficacy data from the Transform-HTN open-label extension trial.
• A conference call will be hosted today, March 12, 2026, at 4:30 p.m. ET to discuss results and provide a corporate update.

Key Dates

Recommendation

The FDA's acceptance of the NDA for lorundrostat for hypertension, a large and underserved market, is a pivotal de-risking event for Mineralys Therapeutics. This, combined with a robust cash position extending into 2028 and a reduced net loss, provides a strong financial foundation. While the Explore-OSA trial missed its primary endpoint for AHI, the core hypertension indication remains on track with positive clinical data and a clear regulatory path. The potential for lorundrostat to address a specific patient population with dysregulated aldosterone offers a differentiated market opportunity, making the stock an attractive "buy" for long-term growth investors.

Keywords

Mineralys Therapeutics, MLYS, lorundrostat, hypertension, FDA, NDA, PDUFA, biopharmaceutical, clinical trials, financial results, Q4 2025, FY 2025, obstructive sleep apnea, chronic kidney disease, aldosterone synthase inhibitor, drug development